Katarina Stingl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katarina Stingl has a total of 709 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Kohl
Institute for Ophthalmic Research, Centre for Ophthalmology, University Hospital Tübingen, 72076 Tübingen, Germany
24 shared publications Susanne Kohl
Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany
14 shared publicationsLaura Kühlewein
University Eye Hospital, Center for Ophthalmology, University of Tuebingen, Germany
13 shared publicationsMelanie Kempf
Department for Ophthalmology, University Eye Clinic, Eberhard Karls University of Tübingen, Tübingen, Germany
12 shared publications- Tobias B. Haack
Institute of Medical Genetics and Applied Genomics, University of Tübingen
11 shared publications Eberhart Zrenner
University Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, Tübingen, Germany
10 shared publications
Latest Publications
- Open Access
Extending the Genotypes and Phenotypes of C1QTNF5-Associated Retinal Disease
Background: Late-Onset Retinal Degeneration (L-ORD) is an inherited retinal dystrophy (IRD) that typically manifests with delayed dark adaptation by the fifth decade of life and progresses to initial central visual impairment after age 60 years. Here, we describe the clinical and molecular characterisation of two C1QTNF5 missense variants identified in individuals with IRD that do not share the characteristic retinal phenotype of L-ORD and exhibit variable age of onset and disease severity. Methods: Probands from two unrelated families underwent genetic testing and comprehensive ophthalmic phenotyping, including multimodal retinal imaging and electrophysiological assessment. This allowed comparison to the previously reported ophthalmic phenotype in two additional families for which the genetic cause of IRD had been previously reported. Genetic analysis was performed using next-generation sequencing, with variants classified according to ACMG/AMP guidelines. In silico analyses assessed evolutionary conservation, predicted pathogenicity, and structural consequences. To experimentally assess variant effects, wild-type and mutant C1QTNF5 constructs were expressed in hTERT-RPE1 cells, and protein folding, stability, and secretion were evaluated. Results: A de novo heterozygous variant, c.548G>A p.(G183E) in C1QTNF5 in a proband, was classified as likely pathogenic. The genetic cause of IRD in the other unrelated probands was C1QTNF5 c.538C>G, p.(Q180E), a known pathogenic variant. The missense variants affect highly conserved residues and are absent from population databases. Structural modelling of both variants predicted destabilisation of C1QTNF5 for both variants, although significantly less severe than for previously identified pathogenic L-ORD variants. In vitro analyses revealed reduced stability of both mutant proteins expressed alone, but when co-expressed with wild-type (WT) C1QTNF5, differences between these variants were observed. In contrast to L-ORD variants, C1QTNF5 containing p.G183E or p.Q180E, could multimerise, generating the expected ratio of trimer and high molecular weight C1QTNF5 multimers. C1QTNF5 p.Q180E/WT co-assembly destabilised the protein and decreased the amount of total C1QTNF5 secreted, but p.G183E was secreted at an equivalent level to WT C1QTNF5. Conclusions: These findings expand the variant and mechanistic spectrum of C1QTNF5-associated retinal disease and highlight C1QTNF5 protein misfolding as a key pathogenic mechanism. Integrating clinical phenotyping with structural and functional analyses is critical for accurate variant interpretation and molecular diagnosis in C1QTNF5-associated retinal disease.
Open AccessExtending the Genotypes and Phenotypes of C1QTNF5-Associated Retinal Disease
Background: Late-Onset Retinal Degeneration (L-ORD) is an inherited retinal dystrophy (IRD) that typically manifests with delayed dark adaptation by the fifth decade of life and progresses to initial central visual impairment after age 60 years. Here, we describe the clinical and molecular characterisation of two C1QTNF5 missense variants identified in individuals with IRD that do not share the characteristic retinal phenotype of L-ORD and exhibit variable age of onset and disease severity. Methods: Probands from two unrelated families underwent genetic testing and comprehensive ophthalmic phenotyping, including multimodal retinal imaging and electrophysiological assessment. This allowed comparison to the previously reported ophthalmic phenotype in two additional families for which the genetic cause of IRD had been previously reported. Genetic analysis was performed using next-generation sequencing, with variants classified according to ACMG/AMP guidelines. In silico analyses assessed evolutionary conservation, predicted pathogenicity, and structural consequences. To experimentally assess variant effects, wild-type and mutant C1QTNF5 constructs were expressed in hTERT-RPE1 cells, and protein folding, stability, and secretion were evaluated. Results: A de novo heterozygous variant, c.548G>A p.(G183E) in C1QTNF5 in a proband, was classified as likely pathogenic. The genetic cause of IRD in the other unrelated probands was C1QTNF5 c.538C>G, p.(Q180E), a known pathogenic variant. The missense variants affect highly conserved residues and are absent from population databases. Structural modelling of both variants predicted destabilisation of C1QTNF5 for both variants, although significantly less severe than for previously identified pathogenic L-ORD variants. In vitro analyses revealed reduced stability of both mutant proteins expressed alone, but when co-expressed with wild-type (WT) C1QTNF5, differences between these variants were observed. In contrast to L-ORD variants, C1QTNF5 containing p.G183E or p.Q180E, could multimerise, generating the expected ratio of trimer and high molecular weight C1QTNF5 multimers. C1QTNF5 p.Q180E/WT co-assembly destabilised the protein and decreased the amount of total C1QTNF5 secreted, but p.G183E was secreted at an equivalent level to WT C1QTNF5. Conclusions: These findings expand the variant and mechanistic spectrum of C1QTNF5-associated retinal disease and highlight C1QTNF5 protein misfolding as a key pathogenic mechanism. Integrating clinical phenotyping with structural and functional analyses is critical for accurate variant interpretation and molecular diagnosis in C1QTNF5-associated retinal disease.
- Open Access
A mutation-agnostic and allele-specific ASO strategy demonstrates potent functional rescue and retinal preservation in RHO-linked retinitis pigmentosa
Autosomal dominant retinitis pigmentosa (adRP) caused by RHO mutations is a leading form of inherited retinal degeneration. Extensive allelic heterogeneity of RHO pathogenic variants limits the translational applicability of mutation-specific gene therapies. To address this, we developed SNARE (SNP-guided Silencing of Aberrant RHO Expression), a mutation- independent, allele-specific antisense oligonucleotide (ASO) strategy. SNARE selectively suppresses mutant RHO transcripts by targeting the common, benign c.-26A/G single- nucleotide polymorphism (SNP) as an allelic discriminator. Candidate gapmer ASOs were screened in engineered reporter lines and validated in patient-derived retinal organoids, identifying RHOligo-A as the lead c.-26A-targeting candidate. In vitro , RHOligo-A achieved robust, preferential knockdown of the target allele, improving RHO localization in retinal organoids, and demonstrated a favorable safety profile with minimal transcriptomic off-target effects and no detectable immunostimulatory activity. Subsequent validation in a novel, humanized RHO P347L/WT mouse model, achieved sustained c.-26A-linked allele-selective suppression, retinal structure preservation, and significantly restored visual function, upon a single intravitreal administration. These findings establish RHOligo-A and SNARE as a scalable, mutation-independent therapeutic platform with strong translational potential and substantial clinical reach for RHO-associated adRP.
Open AccessA mutation-agnostic and allele-specific ASO strategy demonstrates potent functional rescue and retinal preservation in RHO-linked retinitis pigmentosa
Autosomal dominant retinitis pigmentosa (adRP) caused by RHO mutations is a leading form of inherited retinal degeneration. Extensive allelic heterogeneity of RHO pathogenic variants limits the translational applicability of mutation-specific gene therapies. To address this, we developed SNARE (SNP-guided Silencing of Aberrant RHO Expression), a mutation- independent, allele-specific antisense oligonucleotide (ASO) strategy. SNARE selectively suppresses mutant RHO transcripts by targeting the common, benign c.-26A/G single- nucleotide polymorphism (SNP) as an allelic discriminator. Candidate gapmer ASOs were screened in engineered reporter lines and validated in patient-derived retinal organoids, identifying RHOligo-A as the lead c.-26A-targeting candidate. In vitro , RHOligo-A achieved robust, preferential knockdown of the target allele, improving RHO localization in retinal organoids, and demonstrated a favorable safety profile with minimal transcriptomic off-target effects and no detectable immunostimulatory activity. Subsequent validation in a novel, humanized RHO P347L/WT mouse model, achieved sustained c.-26A-linked allele-selective suppression, retinal structure preservation, and significantly restored visual function, upon a single intravitreal administration. These findings establish RHOligo-A and SNARE as a scalable, mutation-independent therapeutic platform with strong translational potential and substantial clinical reach for RHO-associated adRP.
- Open Access
- 7 July 2026
Missense variants in KATNA1 alter microtubule dynamics and underlie dominant macular dystrophy
Inherited retinal diseases (IRDs) encompass a broad spectrum of genetic conditions leading to visual impairment. In this study, we identify KATNA1, encoding the catalytic p60 subunit of the microtubule-severing enzyme katanin, as a previously unrecognized cause of autosomal dominant macular dystr...
- 7 July 2026
Open AccessMissense variants in KATNA1 alter microtubule dynamics and underlie dominant macular dystrophy
Inherited retinal diseases (IRDs) encompass a broad spectrum of genetic conditions leading to visual impairment. In this study, we identify KATNA1, encoding the catalytic p60 subunit of the microtubule-severing enzyme katanin, as a previously unrecognized cause of autosomal dominant macular dystr...
- Open Access
- 20 May 2026
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 153 (1) , 3-11
Clinical endpoints special session, ISCEV 2025, Utrecht
This report summarises the Clinical Endpoints Special Session held during the 62nd annual symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV), convened at Tivoli Vredenburg, Utrecht, The Netherlands. The session brought together clinicians, regulators, industry representatives, and a patient voice to consider the state of clinical endpoints in trials for inherited retinal disorders (IRDs). Discussions covered the adequacy of current endpoints, challenges of disease heterogeneity, regulatory expectations, operational feasibility, and the perspectives of patients. The session highlighted the need to anchor emerging endpoints to clinically meaningful outcomes and to minimise assessment burdens.
- 20 May 2026
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 153 (1) , 3-11
Open AccessClinical endpoints special session, ISCEV 2025, Utrecht
This report summarises the Clinical Endpoints Special Session held during the 62nd annual symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV), convened at Tivoli Vredenburg, Utrecht, The Netherlands. The session brought together clinicians, regulators, industry representatives, and a patient voice to consider the state of clinical endpoints in trials for inherited retinal disorders (IRDs). Discussions covered the adequacy of current endpoints, challenges of disease heterogeneity, regulatory expectations, operational feasibility, and the perspectives of patients. The session highlighted the need to anchor emerging endpoints to clinically meaningful outcomes and to minimise assessment burdens.
- Open Access
- 29 January 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (4) , 101090
Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec
- 29 January 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (4) , 101090
Open AccessExpert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec
- Open Access
Fixel-Based Analysis reveals microstructural visual pathway changes associated with retinal remodeling in retinitis pigmentosa
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy, traditionally considered a photoreceptor degenerative disorder. However, the relationship between retinal degeneration and structural alterations along central visual pathways remains poorly understood. We investigated possible structural links across the retinocortical pathway in 15 genetically characterized RP patients (RHO, PDE6A, PDE6B mutations) compared with 22 healthy controls, using spectral-domain optical coherence tomography (SD-OCT) combined with diffusion-weighted MRI and fixel-based analysis (FBA). Retinal segmentation revealed marked outer layer thinning (outer nuclear layer: −55% foveal, −77% parafoveal) with significant inner layer thickening at the fovea (inner plexiform layer +29%, inner nuclear layer +40%). Parafoveal regions showed near-complete photoreceptor loss but inner retinal thickness approaching normal values. FBA demonstrated significant fiber density reductions in optic tracts and optic radiations, without corresponding macrostructural changes in tract cross-section, suggesting early microstructural disruption preceding atrophy. Correlation analyses revealed significant associations between parafoveal inner plexiform layer thickness and fiber density in both optic tracts (r=0.856) and radiations (r=0.768), with no correlations observed at the foveal level. These findings demonstrate complex, region-specific retinal remodeling in RP, likely reflecting Müller cell gliosis rather than mechanical compensation. The fiber density reduction without tract atrophy suggests trans-synaptic degeneration along visual pathways. This multimodal framework provides insights into structural propagation in inherited retinal dystrophies and may serve as a biomarker for evaluating therapeutic interventions aimed at photoreceptor restoration.
Open AccessFixel-Based Analysis reveals microstructural visual pathway changes associated with retinal remodeling in retinitis pigmentosa
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy, traditionally considered a photoreceptor degenerative disorder. However, the relationship between retinal degeneration and structural alterations along central visual pathways remains poorly understood. We investigated possible structural links across the retinocortical pathway in 15 genetically characterized RP patients (RHO, PDE6A, PDE6B mutations) compared with 22 healthy controls, using spectral-domain optical coherence tomography (SD-OCT) combined with diffusion-weighted MRI and fixel-based analysis (FBA). Retinal segmentation revealed marked outer layer thinning (outer nuclear layer: −55% foveal, −77% parafoveal) with significant inner layer thickening at the fovea (inner plexiform layer +29%, inner nuclear layer +40%). Parafoveal regions showed near-complete photoreceptor loss but inner retinal thickness approaching normal values. FBA demonstrated significant fiber density reductions in optic tracts and optic radiations, without corresponding macrostructural changes in tract cross-section, suggesting early microstructural disruption preceding atrophy. Correlation analyses revealed significant associations between parafoveal inner plexiform layer thickness and fiber density in both optic tracts (r=0.856) and radiations (r=0.768), with no correlations observed at the foveal level. These findings demonstrate complex, region-specific retinal remodeling in RP, likely reflecting Müller cell gliosis rather than mechanical compensation. The fiber density reduction without tract atrophy suggests trans-synaptic degeneration along visual pathways. This multimodal framework provides insights into structural propagation in inherited retinal dystrophies and may serve as a biomarker for evaluating therapeutic interventions aimed at photoreceptor restoration.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 793-798
A CASE OF ACUTE ZONAL OCCULT OUTER RETINOPATHY UNDER IMMUNOMODULATORY TREATMENT
Purpose: To describe the clinical course and treatment response of a case of acute zonal occult outer retinopathy. Methods: This is an observational case report. The examinations included ophthalmic examination, longitudinal multimodal imaging, visual field testing, electrophysiologic recordings, serologic analyses, and whole genome sequencing. Results: In this report, the authors present the case of an otherwise healthy 33-year-old woman with bilateral acute zonal occult outer retinopathy manifestation. Other possible causes of the observed retinal lesions were ruled out by extensive diagnostic workup. Treatment with oral prednisolone therapy led to temporal disease control but progression was observed after prednisolone discontinuation. A tapered oral prednisolone therapy in combination with adalimumab initiation prevented further progression for at least 21 months. Conclusion: Diagnosis of acute zonal occult outer retinopathy is frequently complicated by the unspecific symptoms of the disease and significant number of differential diagnoses. Complete diagnostic workup is important to rule out other etiologies. Owing to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- 1 November 2025
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 793-798
Open AccessA CASE OF ACUTE ZONAL OCCULT OUTER RETINOPATHY UNDER IMMUNOMODULATORY TREATMENT
Purpose: To describe the clinical course and treatment response of a case of acute zonal occult outer retinopathy. Methods: This is an observational case report. The examinations included ophthalmic examination, longitudinal multimodal imaging, visual field testing, electrophysiologic recordings, serologic analyses, and whole genome sequencing. Results: In this report, the authors present the case of an otherwise healthy 33-year-old woman with bilateral acute zonal occult outer retinopathy manifestation. Other possible causes of the observed retinal lesions were ruled out by extensive diagnostic workup. Treatment with oral prednisolone therapy led to temporal disease control but progression was observed after prednisolone discontinuation. A tapered oral prednisolone therapy in combination with adalimumab initiation prevented further progression for at least 21 months. Conclusion: Diagnosis of acute zonal occult outer retinopathy is frequently complicated by the unspecific symptoms of the disease and significant number of differential diagnoses. Complete diagnostic workup is important to rule out other etiologies. Owing to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- Open Access
- 18 August 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (2) , 173-179
Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A -associated retinitis pigmentosa: a non-randomised controlled trial
Purpose: PDE6A -associated retinitis pigmentosa (RP) is a rare inherited retinal disease leading to severe vision loss and blindness, with no available treatment. This study assessed the safety and vision outcomes of a gene therapy using an adeno-associated virus (AAV) vector encoding PDE6A (AAV8.hPDE6A). Methods: In an open-label, non-randomised controlled phase I/IIa trial, nine patients with biallelic PDE6A variants received a single subretinal injection of AAV8.hPDE6A. Doses were either 1.0×10¹⁰ (n=6) or 5.0×10¹⁰ (n=3) total vector genomes. Safety was the primary endpoint, assessed via clinical examinations, laboratory analyses and optical coherence tomography imaging. Secondary outcomes included changes in visual function, such as best corrected visual acuity (BCVA), contrast sensitivity, colour perception, dark adaptation thresholds, visual fields, patient-reported outcomes and chromatic pupil campimetry over 1 year. Results: The mean patient age was 40.1 years, with baseline BCVA ranging from 40 to 82 letters (0.9–0.1 logMAR). No systemic adverse events occurred, and most ocular events resolved without treatment. Persistent adverse events included small peripheral atrophic areas (n=2), disturbed colour discrimination (n=3), cataract (n=1), slight central retinal thinning (n=5) and moderate visual acuity loss (n=2, 1 in each dose group). BCVA, full-field stimulus thresholds and other visual function measures showed statistically non-significant changes, with a trend towards worsening of retinal sensitivity in the treated eyes. Conclusion: Subretinal gene therapy with AAV8.hPDE6A did not improve visual function over 1 year and posed risks, including central retinal thinning and visual acuity decline. This is in contrast to the safety and efficacy profile established in preclinical models.
- 18 August 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (2) , 173-179
Open AccessSafety and vision outcomes of subretinal gene supplementation therapy in PDE6A -associated retinitis pigmentosa: a non-randomised controlled trial
Purpose: PDE6A -associated retinitis pigmentosa (RP) is a rare inherited retinal disease leading to severe vision loss and blindness, with no available treatment. This study assessed the safety and vision outcomes of a gene therapy using an adeno-associated virus (AAV) vector encoding PDE6A (AAV8.hPDE6A). Methods: In an open-label, non-randomised controlled phase I/IIa trial, nine patients with biallelic PDE6A variants received a single subretinal injection of AAV8.hPDE6A. Doses were either 1.0×10¹⁰ (n=6) or 5.0×10¹⁰ (n=3) total vector genomes. Safety was the primary endpoint, assessed via clinical examinations, laboratory analyses and optical coherence tomography imaging. Secondary outcomes included changes in visual function, such as best corrected visual acuity (BCVA), contrast sensitivity, colour perception, dark adaptation thresholds, visual fields, patient-reported outcomes and chromatic pupil campimetry over 1 year. Results: The mean patient age was 40.1 years, with baseline BCVA ranging from 40 to 82 letters (0.9–0.1 logMAR). No systemic adverse events occurred, and most ocular events resolved without treatment. Persistent adverse events included small peripheral atrophic areas (n=2), disturbed colour discrimination (n=3), cataract (n=1), slight central retinal thinning (n=5) and moderate visual acuity loss (n=2, 1 in each dose group). BCVA, full-field stimulus thresholds and other visual function measures showed statistically non-significant changes, with a trend towards worsening of retinal sensitivity in the treated eyes. Conclusion: Subretinal gene therapy with AAV8.hPDE6A did not improve visual function over 1 year and posed risks, including central retinal thinning and visual acuity decline. This is in contrast to the safety and efficacy profile established in preclinical models.
- Open Access
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (11) , 12
Flavoprotein Fluorescence Imaging in Stargardt Disease: Linking Metabolic Stress to Structural Damage
Stargardt disease (SD) is an inherited retinal disorder that leads to progressive vision loss. Currently, no approved treatments exist. Identifying early metabolic changes in the retina could be critical for the development of new therapies. Flavoprotein fluorescence (FPF) imaging has the potential to serve as a non-invasive biomarker for detecting these early changes before structural damage is evident. Therefore, this study evaluated FPF patterns in patients with SD and correlated these findings with structural imaging modalities, specifically fundus autofluorescence (FAF) and optical coherence tomography (OCT). This cross-sectional study enrolled 36 subjects with genetically confirmed ABCA4-associated SD between June 1, 2023, and January 31, 2024, at the University Eye Clinic Tübingen, Germany. FPF patterns were qualitatively and quantitatively analyzed and correlated with FAF and OCT findings to identify distinct lesion types. Several distinct lesion types were identified based on FPF signal patterns and their correlation with FAF and OCT findings. Increased FPF signals were primarily associated with outer retinal damage. In some cases, increased FPF was observed in the absence of significant structural changes, indicating early metabolic stress. This study demonstrates that FPF imaging is a promising tool for detecting early metabolic changes in Stargardt disease, potentially serving as a non-invasive biomarker for monitoring disease progression and treatment response. However, current FPF imaging technology is insufficient to discern true FPF signals from lipofuscin-derived fluorescence, making location-specific and FAF comparative analyses imperative and highlighting the need for longitudinal studies.
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (11) , 12
Open AccessFlavoprotein Fluorescence Imaging in Stargardt Disease: Linking Metabolic Stress to Structural Damage
Stargardt disease (SD) is an inherited retinal disorder that leads to progressive vision loss. Currently, no approved treatments exist. Identifying early metabolic changes in the retina could be critical for the development of new therapies. Flavoprotein fluorescence (FPF) imaging has the potential to serve as a non-invasive biomarker for detecting these early changes before structural damage is evident. Therefore, this study evaluated FPF patterns in patients with SD and correlated these findings with structural imaging modalities, specifically fundus autofluorescence (FAF) and optical coherence tomography (OCT). This cross-sectional study enrolled 36 subjects with genetically confirmed ABCA4-associated SD between June 1, 2023, and January 31, 2024, at the University Eye Clinic Tübingen, Germany. FPF patterns were qualitatively and quantitatively analyzed and correlated with FAF and OCT findings to identify distinct lesion types. Several distinct lesion types were identified based on FPF signal patterns and their correlation with FAF and OCT findings. Increased FPF signals were primarily associated with outer retinal damage. In some cases, increased FPF was observed in the absence of significant structural changes, indicating early metabolic stress. This study demonstrates that FPF imaging is a promising tool for detecting early metabolic changes in Stargardt disease, potentially serving as a non-invasive biomarker for monitoring disease progression and treatment response. However, current FPF imaging technology is insufficient to discern true FPF signals from lipofuscin-derived fluorescence, making location-specific and FAF comparative analyses imperative and highlighting the need for longitudinal studies.
- Open Access
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (8) , 8
Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec
Voretigene neparvovec is approved for RPE65-associated inherited retinal degeneration (RPE65-IRD) in the United States and the European Union. According to current knowledge, early treatment benefits efficacy. However, consensus on treating mild cases is lacking due to ambiguity in balancing clinical benefits with potential side effects. Therefore, we present short-term outcomes of four pediatric patients with milder types of RPE65-IRD. Two unrelated pediatric patients were unilaterally treated at the University Eye Hospital in Tübingen, Germany. Another two unrelated pediatric patients were bilaterally treated at Ghent University Hospital, Belgium. Examinations were performed before and until at least 6 months after treatment, including best-corrected visual acuity, slit-lamp examination, fundus photography, short-wavelength fundus autofluorescence, optical coherence tomography, 90° kinetic perimetry, dark-adapted chromatic perimetry, and full-field stimulus threshold measurements. Despite surgical challenges, treatment with voretigene neparvovec was successful in all four patients. All patients showed rod functional rescue with stable best-corrected visual acuity. Three patients suffered chorioretinal atrophy at the retinotomy site but none developed signs of fast-growing CRA. One case developed limited CRA in the bleb area, potentially related to inflammation in the subretinal space. Treatment with voretigene neparvovec was safe and effective in patients with mild RPE65-IRD. Early treatment showed good functional outcomes. Also, treatment at stages without profound retinal degeneration might lower the risk of fast-growing CRA. This study aids clinical decision-making in unclear cases by demonstrating that early treatment with voretigene neparvovec in mild RPE65-IRD provides functional benefits while minimizing the risk of fast-growing chorioretinal atrophy.
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (8) , 8
Open AccessShort-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec
Voretigene neparvovec is approved for RPE65-associated inherited retinal degeneration (RPE65-IRD) in the United States and the European Union. According to current knowledge, early treatment benefits efficacy. However, consensus on treating mild cases is lacking due to ambiguity in balancing clinical benefits with potential side effects. Therefore, we present short-term outcomes of four pediatric patients with milder types of RPE65-IRD. Two unrelated pediatric patients were unilaterally treated at the University Eye Hospital in Tübingen, Germany. Another two unrelated pediatric patients were bilaterally treated at Ghent University Hospital, Belgium. Examinations were performed before and until at least 6 months after treatment, including best-corrected visual acuity, slit-lamp examination, fundus photography, short-wavelength fundus autofluorescence, optical coherence tomography, 90° kinetic perimetry, dark-adapted chromatic perimetry, and full-field stimulus threshold measurements. Despite surgical challenges, treatment with voretigene neparvovec was successful in all four patients. All patients showed rod functional rescue with stable best-corrected visual acuity. Three patients suffered chorioretinal atrophy at the retinotomy site but none developed signs of fast-growing CRA. One case developed limited CRA in the bleb area, potentially related to inflammation in the subretinal space. Treatment with voretigene neparvovec was safe and effective in patients with mild RPE65-IRD. Early treatment showed good functional outcomes. Also, treatment at stages without profound retinal degeneration might lower the risk of fast-growing CRA. This study aids clinical decision-making in unclear cases by demonstrating that early treatment with voretigene neparvovec in mild RPE65-IRD provides functional benefits while minimizing the risk of fast-growing chorioretinal atrophy.